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Abstract
Aims Smoking is a strong risk factor for albuminuria in people with type 2 diabetes mellitus (T2DM). However, it is unclear 
whether this sequela of smoking is brought about by its action on cardiometabolic parameters or the relationship is independ-
ent. The aim of this systematic review is to explore this relationship.
Methods Electronic databases on cross-sectional and prospective studies in Medline and Embase were searched from Janu-
ary 1946 to May 2018. Adult smokers with T2DM were included, and other types of diabetes were excluded.
Results A random effects meta-analysis of 20,056 participants from 13 studies found that the odds ratio (OR) of smokers 
developing albuminuria compared to non-smokers was 2.13 (95% CI 1.32, 3.45). Apart from smoking, the odds ratio of other 
risk factors associated with albuminuria were: age 1.24 (95% CI 0.84, 1.64), male sex 1.39 (95% CI 1.16, 1.67), duration of 
diabetes 1.78 (95% CI 1.32, 2.23), HbA1c 0.63 (95% CI 0.45, 0.81), SBP 6.03 (95% CI 4.10, 7.97), DBP 1.85 (95% CI 1.08, 
2.62), total cholesterol 0.06 (95% CI − 0.05, 0.17) and HDL cholesterol − 0.01 (95% CI − 0.04, 0.02), triglyceride 0.22 (95% 
CI 0.12, 0.33) and BMI 0.40 (95% CI 0.00–0.80). When the smoking status was adjusted in a mixed effect meta-regression 
model, the duration of diabetes was the only statistically significant factor that influenced the prevalence of albuminuria. In 
smokers, each year’s increase in the duration of T2DM was associated with an increased risk of albuminuria of 0.19 units 
(95% CI 0.07, 0.31) on the log odds scale or increased the odds approximately by 23%, compared to non-smokers. Prediction 
from the meta-regression model also suggested that the odds ratios of albuminuria in smokers after a diabetes duration of 
9 years and 16 years were 1.53 (95% CI 1.10, 2.13) and 5.94 (95% CI 2.53, 13.95), respectively.
Conclusions Continuing to smoke and the duration of diabetes are two strong predictors of albuminuria in smokers with 
T2DM. With a global surge in younger smokers developing T2DM, smoking cessation interventions at an early stage of 
disease trajectory should be promoted.
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Abbreviations
T1DM  Type 1 diabetes mellitus
T2DM  Type 2 diabetes mellitus
HbA1c  Glycosylated haemoglobin
HDL  High-density lipoprotein
LDL  Low-density lipoprotein
SBP  Systolic blood pressure
DBP  Diastolic blood pressure
Introduction
Smokers with T2DM are disproportionately affected by pre-
mature cardiovascular events. A recent systematic review 
of over 1 million people revealed that smokers with T2DM 
were approximately 50% more likely to die prematurely 
with cardiovascular events, compared to non-smokers [1]. 
However, the precise underlying cause for this heightened 
cardiovascular mortality remains unexplored. Smoking 
exacerbates insulin resistance, and adversely affects some 
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cardiometabolic risk factors in T2DM including HbA1c, 
HDL cholesterol and arterial blood pressure [2]. Surpris-
ingly, however, smoking cessation does not appear to con-
fer any substantial cardiovascular risk reduction for up to 
10 years in people with diabetes, compared to 3 years in 
people without [3]. Indeed, the World Health Organization 
(WHO) Multinational Study of Vascular Disease in Diabe-
tes (MSVDD) demonstrated that the risk of cardiovascular 
mortality in people with diabetes remains up to 50% higher 
in recent quitters (1–9 years), compared to non-smokers [4]. 
This incongruous relationship between smoking cessation 
and mortality suggests that there may be some additional 
risk factor/s that contribute to a higher cardiovascular risk 
in recent quitters, which might not be reversed by short-term 
abstinence from smoking.
Albuminuria is an early indicator of both micro-, and 
macrovascular involvements in diabetes [5, 6] and the pro-
gression of albuminuria is a reliable marker for the extent of 
vascular perturbation [7]. Aggressive management of tradi-
tional risk factors such as glucose, blood pressure and lipid 
profile has not shown consistent benefit particularly when 
proteinuria is already established [8]. On the other hand, 
multifactorial interventions including smoking cessation at 
an early stage of disease trajectory have shown promising 
potential for the reversal of microalbuminuria and improved 
cardiovascular outcome [9]. However, conventional risk 
stratification score derived from the HbA1c, blood pressure 
and lipid profile may underestimate the influence of life style 
factors such as obesity and smoking on albuminuria dur-
ing this crucial stage of disease trajectory. With a global 
surge of younger people developing metabolic syndrome and 
T2DM, it is pivotal to explore how best they can be protected 
from albuminuria which not only heralds incipient diabetic 
nephropathy but also poses a higher risk for premature car-
diovascular complications. The aim of this systematic review 
and meta-analysis is to elucidate how smoking impacts upon 
the prevalence of albuminuria and how this relationship is 
influenced by cardiovascular risk factors such as age, male 
sex, duration of diabetes, HbA1c, blood pressure, lipid pro-
file and body mass index (BMI).
Materials and methods
Search strategy and selection criteria
For this systematic review and meta-analysis, we conducted 
a comprehensive search on Medline and Embase electronic 
databases from their inceptions to May 2018. The keywords 
used for the searches were: “type 2 diabetes”, “smoking”, 
“microalbuminuria” or “macroalbuminuria” or “albumi-
nuria” or “proteinuria” in the title, abstract and keywords; 
the result was then combined using the Boolean operator 
“AND”. Additionally, we searched the references of the 
included studies to identify further suitable studies for 
inclusion. We followed the Preferred Reporting Items for 
Systematic Reviews and Meta-analysis Protocol (PRISMA-
P) 2015 guidelines [10] (Fig. 1). We published the proto-
col in the International Prospective Register for Systematic 
Reviews (PROSPERO) database (CRD 42018090637). The 
full search strategy is in Supplementary material 1.
The inclusion criteria were studies reporting urinary 
albumin excretion (UAE) in adults (> 18 years) with T2DM. 
T2DM was defined as a condition affecting people’s blood 
sugar level which was then diagnosed by healthcare pro-
fessionals and treated with diet, lifestyle interventions, oral 
medication or injectable therapy. People with type 1 diabetes 
mellitus (T1DM), steroid-induced diabetes, diabetes insipi-
dus, and late auto-immune diabetes of adults (LADA) were 
excluded, but maturity-onset diabetes of the young (MODY) 
were included. Smokers were defined as self-reported ciga-
rette smokers for at least a year after being diagnosed with 
T2DM. For this study, albuminuria was defined as urinary 
albumin creatinine ratio (ACR) > 20 mg/gm or > 2.5 mg/
mmol in male or > 3.5 mg/mmol in female (KDIGO—
Kidney Disease Improving Global Outcome guidelines 
http://kdigo .org) [11]. Total cholesterol and HDL were 
converted to mmol/l if they were reported in mg/dl (mg/
dl = ÷ 38.67 mmol/l), and TG (mg/dl = ÷ 88.57). HbA1c was 
expressed in both IFCC unit (mmol/mol) and DCCT unit 
(%). Blood pressure was expressed in mm of Hg and BMI 
was expressed as kg/m2.
Studies in English language or translated into the Eng-
lish language were accepted for inclusion. Observational 
prospective and cross-sectional studies were included for 
this review. Two investigators (DK and CLG) independently 
screened the articles using the inclusion and exclusion cri-
teria. Any disagreement between the two investigators was 
resolved either by consensus or by consulting with a third 
investigator (SS). Included studies were selected by review-
ing the titles and abstracts on electronic databases search. 
Additionally, hand searches were carried out from the refer-
ences of the included studies.
Data analysis
Data extraction was conducted using a predesigned data 
extraction template—study name, year of publication, coun-
try of study, study design, number of participants, mean age, 
smoking status of the participants, and presence or absence 
of albuminuria (Table 1).
Study-level data were also compiled for HbA1c, TC, 
HDL cholesterol, triglyceride, BMI, SBP and DBP. Continu-
ous data were expressed as mean ± SD (standard deviation). 
For cross-sectional studies prevalence data, and for prospec-
tive studies baseline data, were extracted. In prospective 
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studies, if albuminuria was absent at the baseline but was 
present at follow-up, then the follow-up data were obtained. 
Extracting data from all studies at just one time point, 
allowed both cross-sectional studies and cohort studies to 
be combined in the meta-analyses. The study team used the 
Newcastle–Ottawa Tool for the assessment of the quality of 
observational studies to assess the quality of included studies 
[12]. A random effect meta-analysis was conducted to assess 
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the odds of having albuminuria between smokers and non-
smokers. Further random effects meta-analyses models were 
fitted to compare participants with and without albuminuria 
for other risk factors (age, sex, duration of type 2 diabetes 
systolic and diastolic blood pressure, total cholesterol, HDL 
cholesterol, triglyceride, BMI and HbA1c), with categori-
cal outcomes fitted as odds ratios and continuous variables 
as difference in mean values. To explore the relationship 
between smoking and albuminuria, meta-regression analy-
ses were carried out. To investigate the influence of dura-
tion of diabetes on the risk of albuminuria between smokers 
and non-smokers further, we used the mixed effect meta-
regression model to predict the odds ratio and corresponding 
95% confidence intervals of albuminuria, among smokers 
compared to non-smokers for the duration of type 2 diabetes 
ranging from 4 to 20 years.
The heterogeneity between studies was assessed using 
the I2 statistic, which represents the total proportion of study 
variation that is due to heterogeneity rather than sampling 
error/chance [13]. Publication bias among studies was 
assessed by visual inspection of the funnel plot and the Egg-
er’s test. The type 1 error to determine the level of statistical 
significance was set at p = 0.05. All statistical analyses were 
carried out using the metafor package (version 2.0.0) in the 
R statistical software environment and Cochrane Collabora-
tion Review Manager version 5.
Results
A total of 2207 studies were identified by electronic data-
base searches. After removing the duplicates, 2119 articles 
were screened for eligibility; 150 of them were accepted 
for abstract review, and 58 of them were included for full-
text review. Overall, 30 studies (20 cross-sectional and ten 
prospective observational) with a total of 113,140 people 
with T2DM were included. The mean age of the study 
participants was 58 years, and 51% of them were male. 
Amongst the study participants, 11% were smokers, 60% 
were non-smokers, and 4% were quitters. Smoking status 
was unavailable for 25% of the study participants. The 
prevalence of albuminuria in the included studies was 
14%. The mean duration of T2DM was 8 years; the mean 
HbA1c was 63 mmol/mol (7.9%), and the mean SBP was 
125 mmHg. The outcomes from the random effects meta-
analysis of 13 studies on 4313 smokers and 15,743 non-
smokers showed that the pooled odds ratio of albuminuria 
in smokers, compared to non-smokers was 2.13 (95% CI 
1.32–3.45; p = 0.002; Fig. 2), indicating a statistically sig-
nificant increased risk of albuminuria in smokers.
Except for one study, the radial plot suggested that the 
outcomes for most of the studies were consistent, regard-
ing the effects of smoking and the variation in the risk of 
albuminuria (Fig. 3).
Fig. 2  Forest plot showing an odds ratio of albuminuria in smokers compared to non-smokers
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The visual exploration of the funnel plot showed slight 
asymmetry of the plot suggesting possible publication bias. 
However, outcomes from the Egger’s test showed the evi-
dence was not statistically significant (p = 0.063) (Supple-
mentary material 2).
Further meta-analyses demonstrated that cardiometabolic 
factors associated with albuminuria (OR, 95% CI) were: age 
1.24 (95% CI 0.84–1.64, p < 0.001); male sex 1.39 (95% 
CI 1.16–1.67; p = 0.003); SBP 6.03 (95% CI 4.10–7.97, 
p < 0.001); DBP 1.85 (95% CI 1.08–2.62, p < 0.001); dura-
tion of T2DM 1.78 (95% CI 1.32–2.23, p < 0.001); BMI 0.40 
(95% CI 0.00–0.80, p = 0.05); total cholesterol 0.06 (95% 
CI − 0.05 to 0.17; p = 0.31); HDL − 0.01 (95% CI − 0.04 
to 0.02; p = 0.47); triglyceride 0.22 (95% CI 0.12–0.33; 
p < 0.001) and HbA1c 0.63 (95% CI 0.45–0.81; p < 0.001) 
(Table 2) (Supplementary material 3).
Meta-regression analyses found most moderator variables 
were not associated with the study effect except the duration 
of diabetes showing a significant association (p = 0.001). We 
observed that the inclusion of duration of diabetes as a mod-
erator variable reduced the residual heterogeneity although 
there was still evidence of residual heterogeneity (Q statis-
tic = 10.09, p = 0.002); the estimate of residual heterogeneity 
(τ2) reduced from 0.69 (95% CI 0.38–3.84) based on the ran-
dom effect meta-analysis model to 0.23 (95% CI 0.10–2.13) 
based on the mixed effect meta-regression model (Table 3) 
(Supplementary material 3). Therefore, the time to diabetes 
as a moderator variable accounted for almost 60% of the 
heterogeneity.
The statistically significant residual heterogeneity sug-
gested that other moderators not investigated in this study 
might be important. The duration of T2DM was positively 
associated with albuminuria: each year increase in the 
duration of T2DM was associated with an increased log of 
odds of albuminuria on an average by 0.19 units (95% CI 
0.07–0.31), or it increased the odds approximately by 21% 
(Fig. 4). After 9 years of diabetes, the odds of albuminuria 
in smokers was approximately 50% higher 1.53 (1.10–2.43) 
compared to non-smokers. The odds ratio rose further to 
almost three times at 12-year duration 2.74 (1.74–4.30) 
and almost six times after 16 years 5.94 (2.58–15.05). The 
predicted mean odds ratio of albuminuria among smokers 
compared to non-smokers conditional on a range of the dura-
tion of diabetes are presented in Supplementary material 4.
Discussion
This systematic review summarises the relationship between 
smoking and albuminuria in people with T2DM, and 
whether this relationship is influenced by other confounding 
variables such as age, sex, the duration of T2DM, HbA1c, 
BMI, HDL and total cholesterol, systolic and diastolic 
blood pressure. The meta-analysis suggests that smoking is 
a strong predictor of albuminuria in people with T2DM. 
The meta-regression, on the other hand, concedes that apart 
from the duration of T2DM, none of the above confounding 
variables has any statistically significant influence on albu-
minuria, when adjusted for smoking status. There is a linear 
relationship between smoking and the duration of T2DM 
with albuminuria. Smokers with T2DM have 21% increased 
annual risk of albuminuria, compared to non-smokers. 
Therefore, smoking cessation at an early stage of disease 
trajectory is likely to be one of the most effective interven-
tion strategies to prevent the development of albuminuria in 
smokers with T2DM.
This is the first systematic review and meta-anal-
ysis exploring the relationship between smoking and 
Fig. 3  A radial plot of random effects meta-analysis showing the 
standardized differences in observed outcomes (zi) between smokers 
against their corresponding precision (xi). The plot demonstrates that 
the differences in outcomes between smokers and non-smokers were 
consistent for most studies suggesting that other factors were unlikely 
to contribute to the variation in the risk of albuminuria
Table 2  Relationship of cardiometabolic risk factors and albuminuria 
before adjusting for smoking status
Variables Mean difference 95% confidence 
interval
p value
Age 1.24 0.84–1.64 < 0.001
Male sex 1.39 1.16–1.67 0.003
SBP 6.03 4.10–7.97 < 0.001
DBP 1.85 1.08–2.62 < 0.001
HbA1c 0.63 0.45–0.81 < 0.001
Duration of dia-
betes
1.78 1.32–2.23 < 0.001
Total cholesterol 0.06 − 0.05 to 0.17 0.31
HDL cholesterol − 0.01 − 0.04 to 0.02 0.47
Triglyceride 0.22 0.12–0.33 < 0.001
Body mass index 0.40 − 0.00 to 0.80 0.05
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albuminuria, and how other cardiometabolic parameters 
influence this relationship. Although multiple studies have 
shown smoking augments the risk of albuminuria in peo-
ple with type 1 diabetes [14, 15], its role in T2DM remains 
undetermined. T2DM, as opposed to T1DM, is one of the 
components of metabolic syndrome. In addition to hypergly-
caemia, it is often accompanied by obesity, hypertension and 
dyslipidaemia [16]. All these risk factors are closely associ-
ated with albuminuria [17], and therefore, the relationship 
between smoking and albuminuria is much more intricate in 
T2DM, compared to T1DM. Previous studies have shown 
that smokers have a higher urinary albumin excretion rate, 
which might have been independent of glycaemic effects 
[18]. Meta-analyses in this systematic review concluded that 
there is a close association between smoking and albumi-
nuria in people with T2DM. Meta-regression, on the other 
hand, taking into consideration all the above confounding 
variables, concluded that the duration of diabetes is the most 
important predictor of albuminuria in smokers with T2DM.
Early detection of albuminuria at the stage of microal-
buminuria, and multifactorial intervention including smok-
ing cessation, are advocated in all the guidelines across 
the globe, including the European Association of Study on 
Diabetes (EASD) and the American Diabetes Association 
(ADA) [19]. This recommendation is based on the obser-
vation that once the daily urinary albumin excretion rate 
reaches the level of proteinuria (urinary albumin excre-
tion > 300 mg/day), no interventions appears to be effective 
in reversing it [20, 21]. Addressing other anthropometric 
and metabolic risk factors including hip–waist ratio, BMI, 
HbA1c, blood pressure and lipid profiles remain at the centre 
of this intervention strategy. For glycaemic management, the 
Table 3  Relationship of 
cardiometabolic risk factors 
with albuminuria after adjusting 
for smoking status
Statistically significant variable that influenced the relationship between smoking and albuminuria was the 
duration of T2DM (highlighted in bold font)
Moderator variables Overall effect size (Z) Heterogeneity (τ2) p value
Age 0.75 (− 0.084–0.18) 0.70 (0.33–6.44) 0.46
Male sex 0.27 (− 0.02–0.03) 0.79 (0.36–6.81) 0.78
HbA1c 1.43 (0.1–0.65) 0.76 (0.30–4.94) 0.15
HDL − 0.50 (− 47.78 to 28.83) 9.93 (1.66–100) 0.61
Total cholesterol 0.92 (− 1.36 to 3.75) 1.74 (0.56–15.78) 0.35
Triglyceride − 1.14 (− 0.51 to 0.14) 0.01 (0–1.28) 0.25
Duration of diabetes 3.18 (0.07–0.31) 0.23 (0.10–2.13) 0.001
SBP 1.09 (− 0.29 to 0.101) 1.26 (0.44–10.22) 0.27
DBP 0.26 (− 0.13 to 0.17) 2.05 (0.66–18.43) 0.79
BMI 2.48 (0.15–1.30) 0.74 (0.36–6.86) 0.93
Fig. 4  Predicted odds ratio 
(OR) of albuminuria in smokers 
compared to non-smokers with 
duration of type 2 diabetes 
based on the outcome of the 
logistic mixed model. The solid 
line shows the predicted mean 
and dashed line shows the 
corresponding 95% confi-
dence interval. The OR below 
the horizontal dotted line is 
not statistically significant 
(p > 0.05). The plot also shows 
the observed OR of individual 
studies (points) where the point 
sizes are proportional to the 
inverse of the corresponding 
standard errors
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choice of drugs seems to be a determinant factor of albu-
minuria. Insulin sensitizers have shown better efficacy in 
halting the prevalence and progression of albuminuria com-
pared to insulin and its secretagogues. In BARI-2D trial, the 
researchers have shown that insulin, and its secretagogues 
are more likely to cause an increased prevalence of albumi-
nuria and coronary artery disease, compared to insulin-sen-
sitizing drugs [22]. However, it will be interesting to know if 
this outcome is influenced by the choice of drugs or people 
who were on insulin had poorer glycaemic control.
Irrespective of hypertension, treatment with angiotensin-
converting enzyme inhibitors (ACEI) or angiotensin receptor 
blockers (ARB) has shown promising prospect of halting the 
prevalence and progression of albuminuria [23]. However, 
studies have shown that this reno-protective effect of ACEI 
and ARBs can be revoked in smokers [24], suggesting that 
renin–angiotensin axis blockade is less effective to prevent 
the progression of albuminuria in smokers. Raised triglyc-
eride, and raised total and LDL cholesterol, with low HDL 
cholesterol are the hallmarks of dyslipidaemia in T2DM 
[25], but in smokers the predominant abnormality in lipid 
profile seems to be lower HDL cholesterol [26]. Smoking 
downregulates the hepatic and endothelial lipoprotein lipase 
activities [27] and tampers with the reverse cholesterol trans-
port pathway [28]. As a consequence, they have lower HDL 
cholesterol compared to their non-smoker counterparts. 
Smoking cessation, on the other hand improves lipid profile 
particularly the HDL cholesterol, despite moderate weight 
gain [29, 30], which in turn halts the progression of albumi-
nuria [31]. Conversely, isolated and piecemeal management 
of glucose, blood pressure and lipid profile did not show 
consistent efficacy to prevent the prevalence or progres-
sion of albuminuria in smokers with diabetes [9, 32]. These 
observations are suggestive of an independent relationship 
between smoking and albuminuria mediated by a constella-
tion of underlying pathophysiological processes.
Several mechanisms have been proposed to explain the 
albuminuria in smokers with T2DM. They include increased 
blood pressure, altered intrarenal haemodynamics such as 
activation of the sympatho-adrenergic pathway, activation of 
the renin–angiotensin–aldosterone axis and the endothelin 
system [33–35]. In addition, smoking directly causes tubulo-
interstitial disease [36] and causes neuro-endocrine disrup-
tion, vascular endothelial damage and metabolic deregula-
tions which adversely affect renal structure and function [18, 
37, 38]. Therefore, addressing hyperglycaemia, hypertension 
and dyslipidaemia without smoking cessation may not halt 
the prevalence and progression of albuminuria in smokers 
with diabetes.
Nicotine and other toxic metabolites in cigarettes appear 
to be handled differently in people with and without diabe-
tes [39]. Nicotine infusion acutely increases insulin resist-
ance in people with T2DM but not in people without [40]. 
Although smokers have lower BMI than non-smokers, 
nonetheless they have more visceral adiposity and lower 
insulin sensitivity [41]. Smoking cessation, on the other 
hand, despite causing moderate weight gain, is associated 
with the reversal of visceral adiposity and an improve-
ment in insulin sensitivity [30]. But this reversal takes 
longer in people with T2DM, compared to people without 
[3, 42]. Therefore, short-term abstinence may not yield 
any meaningful benefit in smokers with T2DM. The Heart 
Outcomes Prevention Evaluation (HOPE) study examined 
the factors that influence the prevalence and progression 
of albuminuria in people with and without diabetes. This 
study demonstrated that smoking, hypertension, older age, 
abdominal adiposity, vascular disease and left ventricular 
hypertrophy were significantly associated with albumi-
nuria, in people with and without diabetes. However, in 
people with diabetes, the most significant determinants 
of albuminuria were the duration of diabetes, HbA1c and 
the use of insulin. People with diabetes were 1.16 times 
more likely to develop albuminuria after a diabetes dura-
tion of 10.4 years (irrespective of their HbA1c), the risk of 
albuminuria increased by 8% for each 0.9% increase in the 
HbA1c, and the people with albuminuria were 1.3 times 
more likely to be on insulin compared to people who had 
normoalbuminuria. Sex, dyslipidaemia, creatinine, and 
BMI were not independently associated with albuminuria 
after adjustment of other factors [43]. Taking all these evi-
dence into account, this systematic review emphasises that 
to effectively manage the prevalence and the progression 
of albuminuria in T2DM, the most effective strategy would 
be a multifactorial intervention where smoking cessation 
is one of the key components.
The findings of this systematic review have significant 
clinical implications. The World Health Organization 
(WHO) estimates that by 2030, a staggering number of 
366 million people will suffer from T2DM worldwide. 
Amongst them, 60 million will be between 20 and 44 
years, and 180 million will be between 45 and 64 years 
[44]. Young smokers with T2DM are at a higher risk of 
albuminuria as they will live longer with the condition. 
This study showed that the risk of albuminuria was simi-
lar in smokers and non-smokers up to around 8.5 years 
of T2DM duration, and then the risk increased approxi-
mately by 20% annually. Albuminuria marks the onset of 
microvascular complications which is often associated 
with retinopathy, neuropathy and macrovascular involve-
ment [45]. Several studies have shown a rapid rise in the 
prevalence of albuminuria and cardiovascular complica-
tions in younger patients with T2DM, compared to T1DM, 
despite having similar glycaemic control [46, 47]. Poor 
lifestyle choices including smoking have been attributed 
to this disparate response of glycaemic control in T2DM, 
as opposed to T1DM. Therefore, this study emphasises 
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that smokers, particularly the younger smokers should be 
encouraged to quit soon after the diagnosis and persuaded 
to remain abstinent.
One of the strengths of this study is that it included all 
the major studies available on the electronic databases from 
their inception and included 30 studies with 113,400 partici-
pants. The quality of the papers was determined by the New-
castle–Ottawa scale, which is a validated tool, and the review 
process followed PRISMA protocol [10], which is consid-
ered to be the gold standard. Publication bias was addressed 
by conducting the appropriate sensitivity test, which did not 
show any significant bias. On the other hand, the weaknesses 
of the study were that it was based mainly on cross-sectional, 
or the baseline data of prospective studies, and therefore, 
no temporal relationship between smoking and albuminu-
ria can be confirmed. Second, most of the included stud-
ies used self-reported smoking behaviour which might not 
be accurate. There was also considerable heterogeneity in 
the included studies, and therefore, the findings may not be 
generalisable. Although between-study heterogeneity was 
investigated, meta-regression models lacked statistical power 
to assess associations between the effect size and study-level 
covariates.
Conclusion
Albuminuria is one of the earliest biochemically measurable 
risk factors in T2DM, which heralds incipient micro- and 
macrovascular complications. It is a substantial milestone 
in the trajectory of disease progression and is independently 
associated with cardiovascular and all-cause mortality. This 
study reiterates that smoking is a strong predictor of albumi-
nuria; the longer the duration of T2DM, the higher the risk. 
With a rapidly changing global prevalence of T2DM with an 
anticipated surge of younger people with T2DM [48], and 
an approximately 70% of them already having complica-
tions [49], it is important to raise awareness about the effect 
of smoking and duration of T2DM on albuminuria, and its 
impact on cardiovascular mortality. Future research should 
be focused on elucidating the relationship between smok-
ing cessation, and the progression of albuminuria in people 
with T2DM, particularly the length of abstinence required 
to reverse the risk of albuminuria.
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